IN2015DN01767A - - Google Patents

Info

Publication number
IN2015DN01767A
IN2015DN01767A IN1767DEN2015A IN2015DN01767A IN 2015DN01767 A IN2015DN01767 A IN 2015DN01767A IN 1767DEN2015 A IN1767DEN2015 A IN 1767DEN2015A IN 2015DN01767 A IN2015DN01767 A IN 2015DN01767A
Authority
IN
India
Prior art keywords
probnp
mortality
transplantation
subjects
prediction
Prior art date
Application number
Inventor
James V Snider
Robert W Gerwien
Sven Jacobson
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Publication of IN2015DN01767A publication Critical patent/IN2015DN01767A/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Abstract

Measurement of circulating ST2 and natriuretic peptide (e.g. NT proBNP) concentrations is useful for the prognostic evaluation of subjects in particular for the prediction of adverse clinical outcomes e.g. mortality transplantation and heart failure.
IN1767DEN2015 2012-08-21 2013-08-21 IN2015DN01767A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261691706P 2012-08-21 2012-08-21
PCT/US2013/056020 WO2014031764A1 (en) 2012-08-21 2013-08-21 Multimarker risk stratification

Publications (1)

Publication Number Publication Date
IN2015DN01767A true IN2015DN01767A (en) 2015-05-29

Family

ID=50148799

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1767DEN2015 IN2015DN01767A (en) 2012-08-21 2013-08-21

Country Status (12)

Country Link
US (4) US20140058743A1 (en)
EP (1) EP2888687B1 (en)
JP (3) JP6450679B2 (en)
CN (2) CN111834009A (en)
AU (3) AU2013305829A1 (en)
CA (1) CA2882303A1 (en)
HK (2) HK1208092A1 (en)
IN (1) IN2015DN01767A (en)
MX (2) MX2015002254A (en)
RU (1) RU2015110054A (en)
SG (2) SG11201501271TA (en)
WO (1) WO2014031764A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US7670769B2 (en) 2002-05-09 2010-03-02 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
JP5383480B2 (en) 2006-04-24 2014-01-08 クリティカル ケア ダイアグノスティクス インコーポレイテッド Predict fatality and detect serious disease
EP3059594A1 (en) 2006-05-01 2016-08-24 Critical Care Diagnostics, Inc. Prognosis of cardiovascular disease
PT2660599E (en) 2008-04-18 2014-11-28 Critical Care Diagnostics Inc Predicting risk of major adverse cardiac events
WO2011127412A2 (en) 2010-04-09 2011-10-13 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
JP6215713B2 (en) 2011-03-17 2017-10-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド How to predict the risk of adverse clinical outcomes
PL2734222T3 (en) 2011-07-18 2017-03-31 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
ES2709697T3 (en) 2012-05-18 2019-04-17 Critical Care Diagnostics Inc Procedures for treatment or prediction of the risk of a ventricular tachyarrhythmia event
CN107478841A (en) 2012-08-16 2017-12-15 重症监护诊断股份有限公司 The method of risk of hypertension is suffered from prediction
SG11201501271TA (en) 2012-08-21 2015-03-30 Critical Care Diagnostics Inc Multimarker risk stratification
CN106461636A (en) * 2014-01-10 2017-02-22 重症监护诊断股份有限公司 Methods and systems for determining risk of heart failure
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US20180252724A1 (en) 2015-08-28 2018-09-06 Mcmaster University Method of Determining Risk of an Adverse Cardiac Event
US20170220749A1 (en) * 2016-02-01 2017-08-03 MD Aware LLC Systems and methods for identifying and using medical calculators
CN109863404A (en) * 2016-04-18 2019-06-07 豪夫迈·罗氏有限公司 For identifying the soluble ST2 of the progress person of LVH in general groups
RU2677611C1 (en) * 2018-04-16 2019-01-17 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Method for predicting adverse cardiovascular events for a period of 12 months in patients with chronic heart failure with recurrence of angina after myocardial revascularization
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
JP7420145B2 (en) * 2019-11-01 2024-01-23 日本電気株式会社 Risk prediction device, risk prediction method, and computer program

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
JPH0731479Y2 (en) 1989-06-02 1995-07-19 内橋エステック株式会社 Thermal fuse
US5217899A (en) 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
JP2665850B2 (en) 1991-11-14 1997-10-22 塩野義製薬株式会社 Monoclonal antibody recognizing the C-terminus of hBNP
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
JP2732005B2 (en) 1992-12-14 1998-03-25 眞一 富永 DNA encoding human ST2, expression product of the DNA, and method for producing expression product by expressing the DNA
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
WO1998007754A1 (en) 1996-08-23 1998-02-26 Human Genome Sciences, Inc. T1 receptor-like ligand ii
WO1998038311A1 (en) 1997-02-28 1998-09-03 Human Genome Sciences, Inc. T1/st2-receptor ligand iii
ES2239801T3 (en) 1997-04-02 2005-10-01 The Brigham And Women's Hospital, Inc. USE OF AN AGENT TO DECREASE THE RISK OF CARDIOVASCULAR DISEASE.
JP5264026B2 (en) 1997-06-10 2013-08-14 エルパス・インコーポレイテッド Methods for early detection of heart disease
US6828107B2 (en) 1997-09-11 2004-12-07 Shionogi & Co., Ltd. Immunoassay method for BNP
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
GB9827348D0 (en) 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
EP1140137A2 (en) 1998-12-18 2001-10-10 Scios Inc. Method for detection and use of differentially expressed genes in disease states
AU5309600A (en) 1999-06-02 2000-12-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
FR2795823B1 (en) 1999-07-01 2001-11-23 Inst Nat Sante Rech Med METHODS AND KITS FOR DIAGNOSING OR MONITORING SYNOVIAL OR OSTEOARTICULAR PATHOLOGY INCLUDING THE USE OF A SPECIFIC MARKER FOR THE DEGRADATION OF SYNOVIAL TISSUE
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
FR2807170B1 (en) 2000-03-30 2002-06-28 Sipal ELASTIC HINGE WITH REDUCED FRICTION
BR0107157A (en) 2000-08-22 2002-07-16 Brigham And Womens Hospital In Diagnosis and treatment of cardiovascular conditions
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US6537221B2 (en) 2000-12-07 2003-03-25 Koninklijke Philips Electronics, N.V. Strain rate analysis in ultrasonic diagnostic images
FI20010019A (en) 2001-01-05 2002-07-06 Biohit Oyj Procedure for the diagnosis of atrophic gastritis
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
DE60235416D1 (en) 2001-05-04 2010-04-01 Biosite Inc Diagnostic markers of acute coronary syndromes and their uses
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en) 2001-11-21 2004-10-26 Pacesetter, Inc. Implantable cardiac stimulation system and method for monitoring diastolic function
US7670769B2 (en) 2002-05-09 2010-03-02 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
US8263325B2 (en) 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
WO2004056868A2 (en) 2002-12-19 2004-07-08 Endocube Sas Nf-hev compositions and methods of use
US20040133079A1 (en) 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
US20040220155A1 (en) 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20050123451A1 (en) 2003-10-31 2005-06-09 Hiroshi Nomura System and apparatus for body fluid analysis using surface-textured optical materials
CA3050151C (en) 2003-11-26 2023-03-07 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
US7781219B2 (en) 2003-12-05 2010-08-24 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (en) 2004-03-31 2005-10-20 Akira Matsumori Examination method of heart disease
PT1849009E (en) 2005-01-24 2009-01-14 Hoffann La Roche Ag F The use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs.
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
US20070021977A1 (en) 2005-07-19 2007-01-25 Witt Biomedical Corporation Automated system for capturing and archiving information to verify medical necessity of performing medical procedure
JP4820192B2 (en) 2006-03-17 2011-11-24 一般財団法人化学及血清療法研究所 Measurement and use of ADAMTS13 in acute coronary syndromes
JP5383480B2 (en) 2006-04-24 2014-01-08 クリティカル ケア ダイアグノスティクス インコーポレイテッド Predict fatality and detect serious disease
ATE517341T1 (en) 2006-04-27 2011-08-15 Critical Care Diagnostics Inc INTERLEUKIN-33 (IL-33) FOR THE DIAGNOSIS AND PREDICTION OF CARDIOVASCULAR DISEASES
EP3059594A1 (en) * 2006-05-01 2016-08-24 Critical Care Diagnostics, Inc. Prognosis of cardiovascular disease
PL2019965T3 (en) 2006-05-02 2015-10-30 Critical Care Diagnostics Inc Differential diagnosis between pulmonary and cardiovascular disease
US8147817B2 (en) 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
RU2312591C1 (en) 2006-06-14 2007-12-20 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" Method for predicting the development of the risk of crib death in patients with left- and right-ventricular extrasystolia
CA2554659A1 (en) * 2006-07-25 2006-11-24 1128971 Alberta Ltd. Hanger flange for hanging a tubular body in a well
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
CA2705500A1 (en) * 2007-05-11 2008-11-20 Tufts Medical Center Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
WO2009040133A1 (en) * 2007-09-26 2009-04-02 Universitätsklinikum Heidelberg Osteopontin as novel prognostic biomarker for heart failure
FR2923029B1 (en) 2007-10-26 2009-11-20 Minima GLASSES OF TYPE WITHOUT ENTOURAGE WITH WIRED BRANCHES
WO2009075566A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
PT2660599E (en) * 2008-04-18 2014-11-28 Critical Care Diagnostics Inc Predicting risk of major adverse cardiac events
WO2010054810A1 (en) * 2008-11-11 2010-05-20 B.R.A.H.M.S Ag Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
CA2765516A1 (en) * 2009-07-01 2011-01-06 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for predicting cardiovascular mortality risk
CN102812359A (en) * 2009-11-13 2012-12-05 Bg医药公司 Risk Factors And Prediction Of Myocardial Infarction
US8258456B2 (en) * 2009-11-27 2012-09-04 Himax Imaging, Inc. Image sensor
WO2011127412A2 (en) 2010-04-09 2011-10-13 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
US20130302841A1 (en) * 2010-11-01 2013-11-14 B.R.A.H.M.S Gmbh Prognosis and risk assessment of patients with non-specific complaints
RU2452394C1 (en) 2010-11-09 2012-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет Method of predicting risk of death of patients with chronic heart failure
JP6215713B2 (en) 2011-03-17 2017-10-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド How to predict the risk of adverse clinical outcomes
PL2734222T3 (en) 2011-07-18 2017-03-31 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
ES2709697T3 (en) 2012-05-18 2019-04-17 Critical Care Diagnostics Inc Procedures for treatment or prediction of the risk of a ventricular tachyarrhythmia event
CN107478841A (en) 2012-08-16 2017-12-15 重症监护诊断股份有限公司 The method of risk of hypertension is suffered from prediction
SG11201501271TA (en) 2012-08-21 2015-03-30 Critical Care Diagnostics Inc Multimarker risk stratification
JP6178687B2 (en) 2013-09-27 2017-08-09 富士機械工業株式会社 Gravure coating equipment
CN106461636A (en) 2014-01-10 2017-02-22 重症监护诊断股份有限公司 Methods and systems for determining risk of heart failure
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
US9934249B2 (en) 2014-06-03 2018-04-03 Conduent Business Machines Services, Llc Systems and methods for context-aware and personalized access to visualizations of road events
USD800333S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800332S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Also Published As

Publication number Publication date
RU2015110054A (en) 2016-10-10
CA2882303A1 (en) 2014-02-27
US10741290B2 (en) 2020-08-11
MX2020009943A (en) 2020-10-16
EP2888687A4 (en) 2016-04-13
JP2020034573A (en) 2020-03-05
MX2015002254A (en) 2015-05-08
US20140058743A1 (en) 2014-02-27
US10303844B2 (en) 2019-05-28
HK1212057A1 (en) 2016-06-03
WO2014031764A1 (en) 2014-02-27
AU2019201709B2 (en) 2021-01-07
US20190237197A1 (en) 2019-08-01
CN111834009A (en) 2020-10-27
AU2019201709A1 (en) 2019-04-04
JP2015532715A (en) 2015-11-12
EP2888687A1 (en) 2015-07-01
CN104737170A (en) 2015-06-24
AU2013305829A1 (en) 2015-03-05
US20200335220A1 (en) 2020-10-22
AU2021202116A1 (en) 2021-05-06
JP2019053086A (en) 2019-04-04
SG10201608854TA (en) 2016-12-29
JP6621520B2 (en) 2019-12-18
EP2888687B1 (en) 2023-08-02
HK1208092A1 (en) 2016-02-19
US20170169179A1 (en) 2017-06-15
JP6450679B2 (en) 2019-01-09
JP6902083B2 (en) 2021-07-14
SG11201501271TA (en) 2015-03-30

Similar Documents

Publication Publication Date Title
IN2015DN01767A (en)
WO2009129454A3 (en) Predicting risk of major adverse cardiac events
MX367046B (en) Pathway specific markers for diagnosing irritable bowel syndrome.
EA201590994A1 (en) METHOD OF INCREASING THE HYDRODYNAMIC VOLUME OF POLYPEPTIDE BY ACQUISITION OF CARBOXIC-CONTAINED GONADOTROPIN PEPTIDE
EA201690213A1 (en) COMPOSITIONS AND METHOD FOR TREATMENT OF CONNECTED STATES
IN2014MN02101A (en)
PH12014502436A1 (en) In vitro method for the diagnosis and surveillance of cancer
MX360479B (en) Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs.
FR3015046B1 (en) METHOD FOR ESTIMATING THE HEALTH CONDITION OF A BATTERY
WO2013167727A3 (en) Method for determining arthritis relapse risk
WO2011085057A3 (en) Methods for detecting insulin autoantibody
GB201114909D0 (en) Biomarkers for lysosomal storage disorders
WO2012122094A3 (en) Biomarkers of cardiac ischemia
BR112013017683A2 (en) method of measuring the concentration of an analyte in an aqueous solution
NZ720311A (en) Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
MX371426B (en) Method for predicting the onset of extrapyramidal symptoms (eps) induced by an antipsychotic-based treatment.
EA201391772A1 (en) METHOD OF DIAGNOSTIC RHEUMATOID ARTHRITIS
FR3015047B1 (en) METHOD FOR ESTIMATING THE HEALTH CONDITION OF A BATTERY
WO2013106851A3 (en) Syncollin, pancreatic triacylglycerol lipase, and other biomarkers for diabetes
PL408305A1 (en) Application of C16 (C16-Cer) ceramide as the biomarker in prediction of premature birth
TR201906948T4 (en) Rehospitalization biomarker after heart failure.
RU2012144141A (en) METHOD FOR EVALUATING THE PROBABILITY OF OCCURRENCE OF FRACTURES IN OSTEOPOROSIS IN WOMEN
UA85502U (en) Method for evaluating prognosis of chronic renal disease with chronic pyelonephritis and hypertension
UA81994U (en) Method for prediction of development of non-stable stenocardia in patients with type 2 diabetes mellitus
UA82989U (en) Method for prediction risk of arterial hypertension occurrence in patients with acromegalia